ZA200903489B - Compositions and methods for treating a neoplasm - Google Patents

Compositions and methods for treating a neoplasm

Info

Publication number
ZA200903489B
ZA200903489B ZA200903489A ZA200903489A ZA200903489B ZA 200903489 B ZA200903489 B ZA 200903489B ZA 200903489 A ZA200903489 A ZA 200903489A ZA 200903489 A ZA200903489 A ZA 200903489A ZA 200903489 B ZA200903489 B ZA 200903489B
Authority
ZA
South Africa
Prior art keywords
neoplasm
compositions
treating
methods
Prior art date
Application number
ZA200903489A
Other languages
English (en)
Inventor
Robert D Mass
Gregory D Plowman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA200903489B publication Critical patent/ZA200903489B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200903489A 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm ZA200903489B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87446006P 2006-12-11 2006-12-11

Publications (1)

Publication Number Publication Date
ZA200903489B true ZA200903489B (en) 2010-08-25

Family

ID=38521756

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903489A ZA200903489B (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm

Country Status (17)

Country Link
US (1) US20100086544A1 (OSRAM)
EP (1) EP2099489B1 (OSRAM)
JP (1) JP2010512407A (OSRAM)
KR (1) KR101320198B1 (OSRAM)
CN (1) CN101547705B (OSRAM)
AU (1) AU2007333565A1 (OSRAM)
BR (1) BRPI0717688A2 (OSRAM)
CA (1) CA2670707A1 (OSRAM)
DK (1) DK2099489T3 (OSRAM)
IL (1) IL198852A (OSRAM)
MX (1) MX2009006202A (OSRAM)
NZ (1) NZ577058A (OSRAM)
RU (1) RU2482877C2 (OSRAM)
SG (1) SG177891A1 (OSRAM)
SI (1) SI2099489T1 (OSRAM)
WO (1) WO2008073509A2 (OSRAM)
ZA (1) ZA200903489B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018260B1 (ru) * 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
PL2488204T3 (pl) 2009-10-16 2016-10-31 Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem dll4 i środków antyhipertensyjnych
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
DK3485903T5 (da) 2011-09-23 2024-09-02 Mereo Biopharma 5 Inc Vegf/dll4-bindende midler og anvendelser deraf
AU2013232208B2 (en) * 2012-03-14 2017-04-27 Indiana University Research And Technology Corporation Compounds and methods for treating leukemia
AU2013337811A1 (en) 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
JP6827415B2 (ja) 2014-10-31 2021-02-10 メレオ バイオファーマ ５ インコーポレイテッド 疾患の処置のための併用療法
DK3330259T3 (da) 2015-07-27 2020-08-10 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
DK3328843T3 (da) 2015-07-27 2023-01-09 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
AU2016299486B2 (en) 2015-07-27 2019-08-01 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP3331864B1 (en) 2015-08-04 2021-11-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
MX384527B (es) 2015-10-12 2025-03-14 Chong Kun Dang Pharmaceutical Corp Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
ES3009668T3 (en) 2018-01-26 2025-03-31 Univ California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
TWI748491B (zh) 2019-05-31 2021-12-01 韓商鐘根堂股份有限公司 作為組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑高鄰苯二甲醯亞胺衍生化合物及包含彼之醫藥組合物
EP4065150A4 (en) 2019-11-25 2023-12-06 The Regents of the University of California LONG-ACTING VEGF INHIBITORS FOR INTRAVASCULAR NEOVASCULARIZATION

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
AU763361B2 (en) * 1998-09-25 2003-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/CDK complexes
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6638965B2 (en) * 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
TWI468417B (zh) * 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體

Also Published As

Publication number Publication date
BRPI0717688A2 (pt) 2013-01-22
CA2670707A1 (en) 2008-06-19
JP2010512407A (ja) 2010-04-22
RU2009126588A (ru) 2011-01-20
NZ577058A (en) 2012-04-27
DK2099489T3 (da) 2014-08-18
WO2008073509A3 (en) 2009-01-08
RU2482877C2 (ru) 2013-05-27
KR20090087908A (ko) 2009-08-18
EP2099489A2 (en) 2009-09-16
SG177891A1 (en) 2012-02-28
AU2007333565A1 (en) 2008-06-19
SI2099489T1 (sl) 2014-09-30
CN101547705A (zh) 2009-09-30
CN101547705B (zh) 2013-06-12
HK1131064A1 (en) 2010-01-15
KR101320198B1 (ko) 2013-10-30
IL198852A (en) 2013-06-27
IL198852A0 (en) 2011-08-01
EP2099489B1 (en) 2014-05-21
WO2008073509A2 (en) 2008-06-19
MX2009006202A (es) 2009-06-22
US20100086544A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
ZA200903489B (en) Compositions and methods for treating a neoplasm
IL257681A (en) Methods and compositions for the treatment of cancer
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
IL193014A0 (en) Methods and compositions for treating schizophrenia
ZA200902860B (en) Compositions and methods for binding sphingosine-1-phosphate
IL198851A0 (en) Methods for treating hypercholesterolemia
EP2078522A4 (en) COMPOSITION FOR THE TREATMENT OF ALLERGIES
ZA200900140B (en) Methods and compositions for treating biofilms
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
IL198310A0 (en) Compositions and method for hair loss prevention
EP2015765A4 (en) METHODS AND COMPOSITIONS FOR TREATING CONDITIONS
ZA200900243B (en) Methods and composition for treating a material
IL210097A0 (en) Compositions and methods for treating unfluenza
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia
MY157996A (en) Desulfurizing coke-water salurry and process for preparation thereof
ZA200806434B (en) Calcium-enrichment compositions and methods for production thereof
GB0621203D0 (en) PLK inhibitors
PL2132251T3 (pl) Kompozycja i sposób
EP2016706A4 (en) METHOD AND ARRANGEMENT FOR VIRTUAL MEETING
GB0625208D0 (en) Composition and method
GB0620930D0 (en) Composition and method for use thereof
EP2094279A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF INFLUENZA
GB0600261D0 (en) Composition and method
GB0607488D0 (en) Composition and process
GB0605004D0 (en) Composition and process